Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189M | $1.56M | $0.00 | $356M | $476M | $327M | $211M | $257M | $26.4M | $42.2M |
| Revenue growth | — | -99.2% | -100.0% | — | 33.6% | -31.4% | -35.4% | 21.9% | -89.7% | 59.8% |
| Operating income | -$116M | -$232M | -$204M | $108M | $156M | -$264M | -$257M | -$203M | -$200M | -$181M |
| Operating margin | -61.2% | -14918.8% | — | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -756.6% | -429.5% |
| Net income | -$127M | -$238M | -$209M | $89.8M | $132M | -$287M | -$292M | -$238M | $28.5M | $168M |
| Net margin | -67.2% | -15306.6% | — | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 108.0% | 398.4% |
| EPS (diluted) | -$3.04 | -$4.48 | -$3.22 | $1.23 | $1.62 | -$3.81 | -$3.76 | -$2.53 | $0.25 | $1.43 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$253M | -$200M | -$159M | $28.4M | $154M | -$37.4M | -$241M | -$175M | -$20.4M | -$139M |
| Capital expenditures | $6.51M | $4.57M | $789K | $1.82M | $7.23M | $1.29M | $2.04M | $286K | — | — |
| Free cash flow | -$259M | -$205M | -$160M | $26.5M | $147M | -$38.7M | -$243M | -$175M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $125M | $127M | $72.4M | $178M | $541M | $417M | $63.5M | $103M | $126M | $88.9M |
| Total assets | $178M | $163M | $99.5M | $409M | $842M | $679M | $481M | $630M | $449M | $258M |
| Total liabilities | $159M | $132M | $138M | $304M | $561M | $582M | $618M | $823M | $581M | $197M |
| Shareholders' equity | $20.5M | $30.5M | -$38.6M | $105M | $281M | $97.7M | -$137M | -$193M | -$132M | $61.0M |
| Retained earnings | -$537M | -$775M | -$985M | -$895M | -$763M | -$1.05B | -$1.34B | -$1.58B | -$1.55B | -$1.38B |
| Shares (wtd avg diluted) | 45.8M | 53.1M | 65.0M | 73.2M | 83.5M | 75.4M | 77.6M | 94.2M | 115M | 117M |
Every figure is extracted from Coherus Oncology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.